{"name":"Leticia Maria Defendi Barboza Marson","slug":"leticia-maria-defendi-barboza-marson","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Testosterone cypionate (200mg/3ml)","genericName":"Testosterone cypionate (200mg/3ml)","slug":"testosterone-cypionate-200mg-3ml","indication":"Deficiency of testosterone biosynthesis","status":"marketed"}]}],"pipeline":[{"name":"Testosterone cypionate (200mg/3ml)","genericName":"Testosterone cypionate (200mg/3ml)","slug":"testosterone-cypionate-200mg-3ml","phase":"marketed","mechanism":"Androgen receptor","indications":["Deficiency of testosterone biosynthesis","Delayed puberty","Hormone receptor positive malignant neoplasm of breast","Klinefelter's syndrome, XXY","LHRH Deficiency"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":0,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}